ACS Medicinal Chemistry Letters
Letter
nonmevalonate pathway of isoprenoid biosynthesis as antimalarial
drugs. Science 1999, 285, 1573−1576.
(7) Missinou, M. A.; Borrmann, S.; Schindler, A.; Issifou, S.;
Adegnika, A. A.; Matsiegui, P. B.; Binder, R.; Lell, B.; Wiesner, J.;
Baranek, T.; Jomaa, H.; Kremsner, P. G. Fosmidomycin for malaria.
Lancet 2002, 360, 1941−1942.
(8) Oyakhirome, S.; Issifou, S.; Pongratz, P.; Barondi, F.; Ramharter,
M.; Kun, J. F.; Missinou, M. A.; Lell, B.; Kremsner, P. G. Randomized
controlled trial of fosmidomycin-clindamycin versus sulfadoxine-
pyrimethamine in the treatment of Plasmodium falciparum malaria.
Antimicrob. Agents Chemother. 2007, 51, 1869−1871.
(23) Steinbacher, S.; Kaiser, J.; Eisenreich, W.; Huber, R.; Bacher, A.;
Rohdich, F. Structural basis of fosmidomycin action revealed by the
complex with 2-C-methyl-D-erythritol 4-phosphate synthase (IspC).
Implications for the catalytic mechanism and anti-malaria drug
development. J. Biol. Chem. 2003, 278, 18401.
(24) Mac Sweeney, A.; Lange, R.; Fernandes, R. P.; Schulz, H.; Dale,
G. E.; Douangamath, A.; Proteau, P. J.; Oefner, C. The crystal
structure of E.coli 1-deoxy-D-xylulose-5-phosphate reductoisomerase in
a ternary complex with the antimalarial compound fosmidomycin and
NADPH reveals a tight-binding closed enzyme conformation. J. Mol.
Biol. 2005, 345, 115−127.
(25) Yajima, S.; Hara, K.; Iino, D.; Sasaki, Y.; Kuzuyama, T.; Ohsawa,
K.; Seto, H. Structure of 1-deoxy-D-xylulose 5-phosphate reductoiso-
merase in a quaternary complex with a magnesium ion, NADPH and
the antimalarial drug fosmidomycin. Acta Crystallogr., Sect. F: Struct.
Biol. Cryst. Commun. 2007, 63, 466−470.
(26) Umeda, T.; Tanaka, N.; Kusakabe, Y.; Nakanishi, M.; Kitade, Y.;
Nakamura, K. T. Molecular basis of fosmidomycin's action on the
human malaria parasite Plasmodium falciparum. Sci. Rep. 2011, 1,
article number 9, DOI: 10.1038/srep00009.
(27) Fernandes, R. P.; Phaosiri, C.; Proteau, P. J. Mutation in the
flexible loop of 1-deoxy-D-xylulose 5-phosphate reductoisomerase
broadens substrate utilization. Arch. Biochem. Biophys. 2005, 444, 159−
164.
(9) Kuntz, L.; Tritsch, D.; Grosdemange-Billiard, C.; Hemmerlin, A.;
Willem, A.; Bach, T. J.; Rohmer, M. Isoprenoid biosynthesis as a target
for antibacterial and antiparasitic drugs: phosphonohydroxamic acids
as inhibitors of deoxyxylulose phosphate reducto-isomerase. Biochem. J.
2005, 386, 127−135.
(10) Merckle, L.; de Andres-Gomez, A.; Dick, B.; Cox, R. J.; Godfrey,
C. R. A fragment-based approach to understanding inhibition of 1-
deoxy-D-xylulose-5-phosphate reductoisomerase. ChemBioChem 2005,
6, 1866−1874.
(11) Munos, J. W.; Pu, X.; Liu, H. W. Synthesis and analysis of a
fluorinated product analogue as an inhibitor for 1-deoxy-D-xylulose 5-
phosphate reductoisomerase. Bioorg. Med. Chem. Lett. 2008, 18, 3090−
3094.
(12) Silber, K.; Heidler, P.; Kurz, T.; Klebe, G. AFMoC enhances
predictivity of 3D QSAR: A case study with DOXP-reductoisomerase.
J. Med. Chem. 2005, 48, 3547−3563.
(13) Kurz, T.; Schluter, K.; Kaula, U.; Bergmann, B.; Walter, R. D.;
̈
Geffken, D. Synthesis and antimalarial activity of chain substituted
pivaloyloxymethyl ester analogues of Fosmidomycin and FR900098.
Bioorg. Med. Chem. 2006, 14, 5121−5135.
(14) Haemers, T.; Wiesner, J.; Van Poecke, S.; Goeman, J.;
Henschker, D.; Beck, E.; Jomaa, H.; Van Calenbergh, S. Synthesis of
α-substituted fosmidomycin analogues as highly potent Plasmodium
falciparum growth inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 1888−
1891.
(15) Woo, Y. H.; Fernandes, R. P.; Proteau, P. J. Evaluation of
fosmidomycin analogs as inhibitors of the Synechocystis sp. PCC6803
1-deoxy-D-xylulose 5-phosphate reductoisomerase. Bioorg. Med. Chem.
2006, 14, 2375−2385.
(16) Kurz, T.; Schluter, K.; Pein, M.; Behrendt, C.; Bergmann, B.;
̈
Walter, R. D. Conformationally restrained aromatic analogues of
fosmidomycin and FR900098. Arch. Pharm. Chem. Life Sci. 2007, 340,
339−344.
(17) Yajima, S.; Hara, K.; Sanders, J. M.; Yin, F.; Ohsawa, K.;
Wiesner, J.; Jomaa, H.; Oldfield, E. Crystallographic structures of two
bisphosphonate:1-deoxyxylulose-5-phosphate reductoisomerase com-
plexes. J. Am. Chem. Soc. 2004, 126, 10824−10825.
(18) Deng, L.; Sundriyal, S.; Rubio, V.; Shi, Z.; Song, Y. Coordination
chemistry based approach to lipophilic inhibitors of 1-deoxy-D-
xylulose-5-phosphate reductoisomerase. J. Med. Chem. 2009, 52,
6539−6542.
(19) Deng, L.; Endo, K.; Kato, M.; Cheng, G.; Yajima, S.; Song, Y.
Structures of 1-deoxy-D-xylulose-5-phosphate reductoisomerase/lip-
ophilic phosphonate complexes. ACS Med. Chem. Lett. 2011, 2, 165−
170.
(20) Deng, L.; Diao, J.; Chen, P.; Pujari, V.; Yao, Y.; Cheng, G.;
Crick, D. C.; Prasad, B. V. V; Song, Y. Inhibition of 1-deoxy-D-
xylulose-5-phosphate reductoisomerase by lipophilic phosphonates:
SAR, QSAR, and crystallographic studies. J. Med. Chem. 2011, 54,
4721−4734.
(21) Cai, G.; Deng, L.; Fryszczyn, B. G.; Brown, N. G.; Liu, Z.; Jiang,
H.; Palzkill, T.; Song, Y. Thermodynamic investigation of inhibitor
binding to 1-deoxy-D-xylulose-5-phosphate reductoisomerase. ACS
Med. Chem. Lett. 2012, 3, 496−500.
(22) Yajima, S.; Nonaka, T.; Kuzuyama, T.; Seto, H.; Ohsawa, K.
Crystal structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase
complexed with cofactors: Implications of a flexible loop movement
upon substrate binding. J. Biochem. 2002, 131, 313−317.
282
dx.doi.org/10.1021/ml300419r | ACS Med. Chem. Lett. 2013, 4, 278−282